Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Deleobuvir: Completed Phase III enrollment

Boehringer completed enrollment of 498 treatment-naïve patients with HCV genotype 1b infection in the double-blind, placebo-controlled, international Phase III HCVerso2 trial

Read the full 213 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE